2401 4TH AVE., SEATTLE, WA
Reports 3Q25 Financial Results And Provides A Business Update
Material Contracts, Material Modifications to Rights of Security Holders
Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Reports 2Q25 Financial Results And Provides A Business Update
Shareholder votes
Annual Report to Security Holders
Other Events
Q3
Q2
FY 2023
Q1
S-1
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership